Compare MSGE & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGE | ANIP |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | MSGE | ANIP |
|---|---|---|
| Price | $54.14 | $78.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $49.80 | ★ $105.83 |
| AVG Volume (30 Days) | 290.0K | ★ 397.1K |
| Earning Date | 02-05-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.72 | ★ 1.67 |
| Revenue | ★ $962,282,000.00 | $826,880,000.00 |
| Revenue This Year | $9.47 | $44.06 |
| Revenue Next Year | $5.43 | $9.06 |
| P/E Ratio | $74.86 | ★ $47.13 |
| Revenue Growth | 0.68 | ★ 48.87 |
| 52 Week Low | $28.29 | $52.74 |
| 52 Week High | $55.75 | $99.50 |
| Indicator | MSGE | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 35.72 |
| Support Level | $51.36 | $80.27 |
| Resistance Level | $54.70 | $82.78 |
| Average True Range (ATR) | 1.21 | 2.21 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 60.71 | 5.23 |
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.